Kazia therapeutics is collaborating with the Alliance for Clinical Trials in Oncology Foundation to launch a Phase II study to investigate its brain cancer therapies targeted at tumors’ genetic profile.
The Jumpstarting Brain Tumor Drug Development Coalition (JBTDDC) is offering a new consensus protocol for magnetic resonance imaging (MRI) in brain tumor clinical trials to help in the assessment of whether a new treatment is effective.
Neurosurgeons have developed and used a novel intra-arterial (IA) technique to deliver Avastin (bevacizumab) directly into a malignant brain tumour, potentially administering a higher dose with reduced toxicity.
in-PharmaTechnologist’s periodic round up of developments in the field of drug delivery includes BioDelivery initiating Phase I studies, success for Titan and a novel use for Viagra.
A team of US researchers have uncovered a cocktail of three drugs
that could be effective at treating every patient with a particular
type of brain cancer that typically has a dismal prognosis.
Schering-Plough has entered into an agreement with Oncomethylome
Sciences (OMS), which allows the pharma giants to use OMS
Pharmacogenomic technology to study MGMT methylation status in
brain cancer patients.
Research scientists have targeted alterations in a human
chromosome, which can be used to improve the diagnosis and
treatment of brain tumours in adults that currently account for
over 50 per cent of primary tumours.
US researchers think they have found promising new molecular
targets and treatment approaches for malignant brain tumours,
suggesting a new therapy for anti-cancer drugs.
With the absence of any truly effective drug treatment for brain
tumours, news of researchers working on innovative treatments for
one of the deadliest tumour types raises the possibility of
readdressing the current situation and...